Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 9/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890492 | 0.83 | PIK3CD (0.56) | PIK3CDCYP3A4CYP2D6CYP2C9ALDH1A1 | |
| SCHEMBL10120334 | 0.80 | PIK3CD (0.47) | PIK3CDCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL890530 | 0.78 | PIK3CD (0.57) | PIK3CDHPGDALDH1A1KCNA5 | |
| SCHEMBL2715326 | 0.78 | PIK3CD (0.51) | PIK3CDCYP3A4CYP2D6CYP2C9HPGD | |
| SCHEMBL890613 | 0.76 | PIK3CD (0.58) | PIK3CDHPGDALDH1A1 | |
| SCHEMBL10107431 | 0.76 | PIK3CD (0.57) | PIK3CDHPGDALDH1A1 | |
| Hydrochloric Acid SCHEMBL890601 | 0.75 | PIK3CD (0.56) | PIK3CDHPGDALDH1A1 | |
| SCHEMBL890579 | 0.71 | PIK3CD (0.53) | PIK3CD | |
| SCHEMBL21705350 | 0.70 | HPGD (0.48) | CYP3A4CYP2D6CYP2C9HPGDLMNA | |
| SCHEMBL890466 | 0.69 | PIK3CD (0.58) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083502-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CD 24/4885CYP3A4 2773/4885CYP2D6 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.